Best in Biotech 27 Feb 2024 Japan’s ten hottest biotech companies in healthcare …model, enabling the generation of peptide libraries for hit finding. PeptiDream’s pipeline is diverse and spans a range of therapeutic areas, including oncology, CNS disorders, and immunology. With over 120… February 27, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 12 Apr 2024 Redefining chronic pain treatment …Doloromics is delineating the idea of nociception versus pain itself. Nociception is the central nervous system (CNS) and peripheral nervous system (PNS) processing noxious stimuli. When nociceptors and their pathways… April 12, 2024 - 10 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Nov 2021 Big Pharma Strikes Megadeals In Targeted Protein Degradation …on this as well as oncology targets, several of which are not accessible by PROTACs. “Dunad’s platform is designed to enable the development of orally bioavailable and CNS-accessible monovalent protein degraders – an approach… November 12, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 CRISPR/Cas9: Challenges and outlook from an investor’s perspective …viability of CRISPR/Cas9 therapeutics for common conditions is the ability to penetrate the CNS and other tissues such as muscles. This is where novel delivery systems come into play. What… October 17, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 14 Jun 2023 How are biotechs addressing rare chromosome disorders? …spinal canal, GTX-102 works by reactivating the expression of the paternal UBE3A allele in neurons of the central nervous system (CNS). This has been linked to improved neurological symptoms in… June 14, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Expert Advice 15 Mar 2024 Is biotechnology a good career? Here are the pros and cons …expanding, offering ample opportunities for career advancement, as well as being able to apply your skills across different types of companies, e.g. from CNS [central nervous system] to oncology,” said… March 15, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Jan 2025 Ten drugs to watch in 2025: will these therapies become blockbusters? …giant Lilly several decades ago. Xanomeline, which is a muscarinic agonist that stimulates the muscarinic M1 and M4 receptors in the central nervous system (CNS) by crossing the blood-brain barrier,… January 8, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients …best-in-class profile for CNS diseases. It has demonstrated brain penetration and a favorable safety profile. It showed robust preclinical proof-of-concept in animal models of multiple diseases by modulating pathways leading… June 8, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 May 2023 Six women’s health companies you should know about …receptors outside the central nervous system (CNS), currently in development. Founded in 2009, the company has amassed a total of $53.7 million over 10 funding rounds. HERA Biotech Affecting around… May 18, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 Noema Pharma raises $112 million in Series B financing Noema Pharma, a Swiss clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, has closed an oversubscribed Series B financing round, raising CHF 103 million ($112 million) from new… March 8, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 17 Jul 2017 Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares …market.” Speaking to the broad reach of GPCRs, Marshall told me, “We’ve also built up significant expertise in the CNS area,” making the field a prime target for Heptares’ next… July 17, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Jun 2024 Spotlight on Georgia’s biotech industry: Seven companies to know about in 2024 …stroke, subarachnoid hemorrhage, and treatment-resistant depression by developing small-molecule therapeutics for central nervous system (CNS) disorders. NeurOp’s technology focuses on N-methyl-D-aspartate receptor (NMDAR) antagonists, specifically targeting the GluN2B subunit. NMDARs… June 25, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email